Score Overview
Explore the 2021 public Archive ranking →
Where Sarepta Therapeutics Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- SRPT
2003: 92.7% · 2021: 63.9% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 18.64 | — |
1 Year2025-09-29 | $ 18.82 | -0.96% |
5 Years2021-09-29 | $ 88.77 | -79.00% |
10 Years2016-09-29 | $ 60.98 | -69.43% |
20 Years2006-09-29 | $ 21.84 | -14.65% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 |
|---|---|---|---|---|---|
| Price | $ 18.64 | $ 18.82 | $ 88.77 | $ 60.98 | $ 21.84 |
| Return | — | -0.96% | -79.00% | -69.43% | -14.65% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1.97B | -$ 136M | $ 788M |
| 2025 | $ 2.19B | -$ 713M | $ 939M |
| 2024 | $ 1.90B | $ 235M | $ 1.35B |
| 2023 | $ 1.24B | -$ 535M | $ 1.67B |
| 2022 | $ 933M | -$ 703M | $ 1.98B |
| 2021 | $ 701M | -$ 418M | $ 2.11B |
| 2020 | $ 540M | -$ 554M | $ 1.93B |
| 2019 | $ 380M | -$ 715M | $ 1.12B |
| 2018 | $ 301M | -$ 361M | $ 1.17B |
| 2017 | $ 154M | -$ 50M | $ 1.07B |
| 2016 | $ 5M | -$ 267M | $ 317M |
| 2015 | $ 1M | -$ 220M | $ 192M |
| 2014 | $ 9M | -$ 135M | $ 210M |
| 2013 | $ 14M | -$ 111M | $ 256M |
| 2012 | $ 37M | -$ 121M | $ 187M |
| 2011 | $ 46M | -$ 2M | $ 39M |
| 2010 | $ 29M | -$ 32M | $ 33M |
| 2009 | $ 17M | -$ 25M | $ 48M |
| 2008 | $ 21M | -$ 23M | $ 11M |
| 2007 | $ 10M | -$ 27M | $ 25M |
| 2006 | $ 115.29K | -$ 31M | $ 33M |
| 2005 | $ 4M | -$ 16M | $ 47M |
| 2004 | $ 430.46K | -$ 24M | $ 19M |
| 2003 | $ 969.87K | -$ 14M | $ 37M |
| 2002 | $ 836.78K | -$ 29M | $ 19M |
| 2001 | $ 706.1K | -$ 26M | $ 25M |
| 2000 | $ 1M | -$ 9M | $ 32M |
| 1999 | $ 100K | -$ 8M | $ 11M |
| 1998 | $ 200K | -$ 26M | $ 8M |
| IPO1997 | $ 100K | -$ 3M | $ 17M |
Sarepta Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 540M to $ 2.19B and net income went from -$ 554M to -$ 713M. Revenue increased in 4 of those 5 years; net income in 3.
Across Sarepta Therapeutics Inc's full reported history, from 1997 to 2025, revenue grew from $ 100K to $ 2.19B and net income went from -$ 3M to -$ 713M. Revenue increased in 66% of the years measured; net income in 45%.
Sarepta Therapeutics Inc currently holds a 20-year HDB Score of 3.7 out of 10. How the HDB Score is calculated.
Membership
Continue SRPT’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
